Terms ending in 2030
Every in-force patent on Immunocore Limited's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,361,794 | Cells Expressing a Modified T Cell Receptor In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 10,420,846 | Bifunctional Polypeptides In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 10,517,960 | Bifunctional Polypeptides In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 10,576,162 | Bifunctional Polypeptides In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 8,519,100 | Non-naturally occurring T cell receptors In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 9,068,178 | Nucleic Acid Molecules Encoding Non-Naturally Occurring T Cell Receptors and Cells Thereof In force · High confidence | Immunocore Ltd. | In force | High confidence | |
| US 10,130,721 | Bifunctional Polypeptides In force · High confidence | Immunocore Limited | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.